文献速递药物不良反应与药物警戒

欧洲医疗专业人员对直接医疗专业沟通(DHPC)的认知与特定药物安全问题知晓度调查

Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.
PubMed 文献 · Drug Saf · 2018-01-01

该调查覆盖九国3288名全科医生、药师和心脏科医生,评估其对DHPC的熟悉度及对四种药物安全问题的知晓度。多数(92%)熟悉DHPC,但不同专业对特定安全问题知晓度差异明显,心脏科医生对非心脏药物相关安全问题知晓较低。DHPC是重要信息来源,但网站/通讯等其他渠道也常被使用。

要点

  • 全科医生和药师对DHPC熟悉度较高,但不同专业对特定药物安全问题知晓度存在差异。
  • 心脏科医生对非心脏科药物(即使有心血管风险)的安全问题知晓度较低。
  • DHPC是重要信息来源,但网站/通讯等其他渠道也常被使用,提示需多渠道沟通。

核心结论

  • 全科医生、心脏科医生和药师对DHPC的熟悉程度相似(均较高),但对特定药物安全问题的知晓度存在差异。
  • 心脏科医生对非心脏科药物相关安全问题知晓度较低,即使这些药物具有心血管安全性顾虑。
  • DHPC是各专业获取特定安全问题的重要来源,但其他来源(网站/通讯)也常被使用。

研究设计与样本

  • 基于网络的调查,覆盖九个欧洲国家(克罗地亚、丹麦、爱尔兰、意大利、荷兰、挪威、西班牙、瑞典、英国)的全科医生、心脏科医生和药师。
  • 共纳入3288名受访者,其中全科医生54%、药师40%、心脏科医生7%;各国受访者数量从丹麦的67人到西班牙的916人不等。
  • 调查在SCOPE联合行动框架下进行,询问受访者对DHPC的总体熟悉度及对最近沟通的四种药物(复方激素避孕药、双氯芬酸、丙戊酸、伊伐布雷定)安全问题的知晓度。

主要发现

  • 92%的受访者熟悉DHPC;意大利药师比全科医生更熟悉(99% vs 90%,P=0.004)。
  • 全科医生对双氯芬酸问题知晓度最高(96%),对伊伐布雷定问题最低(70%);药师类似(双氯芬酸91%至伊伐布雷定66%)。
  • 心脏科医生对伊伐布雷定问题知晓度最高(91%),对丙戊酸问题最低(34%)。
  • DHPC是全科医生(范围:45%[避孕药]至60%[丙戊酸])、心脏科医生(33%[避孕药]至61%[丙戊酸])、药师(41%[避孕药]至51%[伊伐布雷定])知晓特定安全问题的常见来源,其次是网站或通讯信息。

临床怎么用

  • 临床药师应关注DHPC作为药物安全信息传递工具的有效性,并注意不同专业间知晓度的差异。
  • 针对非本专业领域但具有相关风险的药物安全问题,需考虑额外策略以提高专科医生的知晓度。
  • 国家主管机构应考虑使用多种来源(如网站、通讯等)沟通重要安全问题,而非仅依赖DHPC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: National competent authorities (NCAs) use Direct Healthcare Professional Communications (DHPCs) to communicate new drug safety issues to healthcare professionals (HCPs). More knowledge is needed about the effectiveness of DHPCs and the extent to which they raise awareness of new safety issues among HCPs. OBJECTIVE: The objective was to assess and compare general practitioners' (GPs'), cardiologists', and pharmacists' familiarity with DHPCs as communication tools, their awareness of specific drug safety issues, and the sources through which they had become aware of the specific issues. METHODS: GPs, cardiologists, and pharmacists from nine European countries (Croatia, Denmark, Ireland, Italy, the Netherlands, Norway, Spain, Sweden, and the UK) completed a web-based survey. The survey was conducted in the context of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action. Respondents were asked about their familiarity with DHPCs in general and their awareness of safety issues that had recently been communicated and involved the following drugs: combined hormonal contraceptives, diclofenac, valproate, and ivabradine. Those HCPs who were aware of the specific safety issues were subsequently asked to indicate the source through which they had become aware of them. Differences between professions in familiarity with DHPCs and awareness were tested using a Pearson χ2 test per country and post hoc Pearson χ2 tests in the case of statistically significant differences. RESULTS: Of the 3288 included respondents, 54% were GPs, 40% were pharmacists, and 7% were cardiologists. The number of respondents ranged from 67 in Denmark to 916 in Spain. Most respondents (92%) were familiar with DHPCs, with one significant difference between the professions: pharmacists were more familiar than GPs in Italy (99 vs 90%, P = 0.004). GPs' awareness ranged from 96% for the diclofenac issue to 70% for the ivabradine issue. A similar pattern was shown for pharmacists (91% aware of the diclofenac issue to 66% of the ivabradine issue). Cardiologists' awareness ranged from 91% for the ivabradine issue to 34% for the valproate issue. Overall, DHPCs were a common source through which GPs (range: 45% of those aware of the contraceptives issue to 60% of those aware of the valproate issue), cardiologists (range: 33% for the contraceptives issue to 61% for the valproate issue), and pharmacists (range: 41% for the contraceptives issue to 51% for the ivabradine issue) had become aware of the specific safety issues, followed by information on websites or in newsletters. CONCLUSIONS: GPs, cardiologists, and pharmacists were to a similar extent (highly) familiar with DHPCs, but they differed in awareness levels of specific safety issues. Cardiologists were less aware of safety issues associated with non-cardiology drugs even if these had cardiovascular safety concerns. This implies that additional strategies may be needed to reach specialists when communicating safety issues regarding drugs outside their therapeutic area but with risks related to their field of specialisation. DHPCs were an important source for the different professions to become aware of specific safety issues, but other sources were also often used. NCAs should consider the use of a range of sources when communicating important safety issues to HCPs.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. de Vries ST, van der Sar MJM, Coleman AM, et al. Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study. Drug Saf. 2018. PMID: 29500798. doi:10.1007/s40264-018-0643-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。